Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 1.00 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.85 |
| ▸ | NT5E | P21589 | 1/20 | 0.81 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.70 |
| ▸ | TOP2A | P11388 | 2/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124 | 1.00 | BRD4 (1.00) | BRD4NT5C2NT5ECREBBPTOP2A | |
| SCHEMBL8381776 | 0.99 | BRD4 (0.97) | BRD4NT5C2NT5ECREBBPTOP2A | |
| SCHEMBL6463477 | 0.96 | BRD4 (0.92) | BRD4NT5C2NT5ECREBBPTOP2A | |
| SCHEMBL9230081 | 0.83 | BRD4 (1.00) | BRD4NT5C2NT5ECREBBPNPC1 | |
| SCHEMBL23683051 | 0.82 | CREBBP (1.00) | BRD4NT5C2NT5ECREBBPTOP2A | |
| SCHEMBL3038563 | 0.82 | NPC1 (0.76) | BRD4NT5C2NT5ECREBBPTOP2A | |
| SCHEMBL22118772 | 0.82 | BRD4 (0.68) | BRD4NT5C2NT5ECREBBPTOP2A | |
| SCHEMBL10644711 | 0.81 | BRD4 (0.68) | BRD4NT5C2NT5ECREBBPTOP2A | |
| SCHEMBL5694052 | 0.81 | BRD4 (0.67) | BRD4NT5C2NT5ECREBBPBTK | |
| SCHEMBL8121393 | 0.81 | STAT3 (0.69) | BRD4NT5C2NT5ECREBBPBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731763-A1 | LRRK2-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2026044046-A1 | PATTERNED MODIFIED OLIGONUCLEOTIDES FOR EXTENDED DURATION OF ACTION | IONIS PHARMACEUTICALS, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4673453-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS FOR RNA INTERFERENCE AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2026-01-07 | — | — | EP | disclosed |
| US-20250382617-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS FOR RNA INTERFERENCE AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2025-12-18 | — | — | US | disclosed |
| EP-4647124-A2 | THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | UCL Business Ltd (GB) | 2025-11-12 | — | — | EP | disclosed |
| EP-4622985-A1 | METHODS FOR DEPROTECTING AND PURIFYING OLIGONUCLEOTIDE COMPOUNDS | Ionis Pharmaceuticals, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4259796-B1 | THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | UCL BUSINESS LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025151895-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-07-17 | — | — | WO | disclosed |
| EP-4577553-A2 | EFFICIENT METHOD FOR MAKING HIGHLY PURIFIED 5'-CAPPED OLIGONUCLEOTIDES | TriLink BioTechnologies, LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4558148-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Amylyx Pharmaceuticals Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2022159712-A1 | COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-4022059-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022133278-A2 | COMPOUNDS AND METHODS FOR MODULATING FACTOR XII | IONIS PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127914-A1 | NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2022-06-23 | — | — | WO | disclosed |
| EP-4013767-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013428-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022122872-A1 | THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | UCL BUSINESS LTD (GB) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022109139-A1 | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3976788-A1 | OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE | Deep Genomics Incorporated (CA) | 2022-04-06 | — | — | EP | disclosed |
| EP-3947684-A1 | COMPOUNDS AND METHODS FOR MODULATING UBE3A-ATS | Ionis Pharmaceuticals, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |